Multicenter registry study of cerebral venous thrombosis in china (RETAIN‐CH): Rationale and design

Author:

Bian Hetao1,Wang Xia2,Liu Lan3,Yan Feng4,Lu Shan5,Hui Wen6,Zhou Chen1,Duan Jiangang7,Li Min8,Chen Jian4,Meng Ran8,Cao Lei9,Wang Longde9,Ji Xunming14ORCID

Affiliation:

1. Beijing Institute for Brain Disorders Capital Medical University Beijing China

2. The George Institute for Global Health University of New South Wales Sydney Australia

3. School of Statistics University of Minnesota at Twin Cities Minneapolis Minnesota USA

4. Department of Neurosurgery Xuanwu Hospital of Capital Medical University Beijing China

5. Department of Neurology and Psychiatry Beijing Shijitan Hospital Capital Medical University Beijing China

6. Department of Science and Technology West China Hospital of Sichuan University Chengdu Sichuan China

7. Department of Emergency Xuanwu Hospital of Capital Medical University Beijing China

8. Department of Neurology Xuanwu Hospital of Capital Medical University Beijing China

9. The General Office of Stroke Prevention Project Committee National Health Commission of the People's Republic of China Beijing China

Abstract

AbstractBackground and rationaleCerebral venous thrombosis (CVT) is a rare cerebrovascular disorder that mainly affects young and middle‐aged adults. Epidemiological data on the incidence, risk factors, diagnosis, treatment, and prognosis of CVT are lacking in China. In addition, there is a lack of evidence from large, multicenter, real‐world studies on the efficacy and safety of endovascular.AimTo understand the incidence, diagnosis and treatment status of CVT in China and to estimate the effectiveness and safety of endovascular treatment in the real‐world.MethodsA multicenter, retrospective observational cohort study will be conducted on CVT patient records from 104 hospitals, between January 1, 2018 and June 30, 2022, identified using a 2‐stage cluster sampling design based on per capita gross domestic product. Each enrolled participant is required to complete a further follow‐up, which includes the current situation and the assessment at 3 and 12 months after discharge.Study outcomesThe outcomes of this study will include the current status of the incidence, pathogenesis, etiology, clinical symptoms, diagnosis, and treatment of CVT in China, as well as the effectiveness and safety of endovascular treatment in the real‐world.DiscussionResults from this study will provide evidence on the incidence, specific risk factors, symptomatic and imaging features, and clinical outcomes of CVT in China as well as indicate whether endovascular treatment is superior to medical management alone for patients with acute CVT in the real‐world.Trial registrationhttp://www.clinicaltrials.gov.IdentifierNCT05448248

Funder

Beijing Science and Technology Planning Project

National Natural Science Foundation of China

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3